login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia
-- In three six-week clinical trials, INVEGA demonstrated statistically significant symptom improvement on the PANSS versus placebo across all doses investigated. INVEGA was also superior to placebo on the PSP in these trials. In a chronic treatment trial, adult patients with schizophrenia who were treated with INVEGA showed a significantly longer time to relapse compared to placebo.
-- From the three six-week clinical trials, treatment-emergent adverse events(iv) (TEAEs) reported in 5% or more of subjects treated with INVEGA and at least twice the placebo rate for at least one dose included: akathisia (i.e. restlessness) and extrapyramidal disorder e.g. involuntary movements, tremors or muscle stiffness).
-- In the three six-week clinical trials, discontinuation rates due to TEAEs for all INVEGA dose groups were low and comparable to placebo (5% for placebo and for INVEGA: 2% for 3 mg, 6% for 6 mg, 4% for 9 mg, 5% for 12 mg).
Worldwide, it is estimated that 1 person in every 100 develops schizophrenia, one of the most serious types of mental illness. In the United States, there are currently 2,000,000 people with schizophrenia, with men and women affected in nearly equal numbers. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions, and social withdrawal), as well as by disorganized thinking.
INVEGA was approved in the U.S. in December 2006, and was the first new prescription treatment for schizophrenia to be approved by the U.S. FDA since 2003. In April 2007, INVEGA was also approved by the FDA for the long-term maintenance treatment of schizophrenia. INVEGA was discovered and jointly developed by ALZA Corporation and Johnson & Johnson Pharmaceutical Research and Development, LLC. Source: PR Newswire
Source-IANS
LIN/M
|
|
|
More News on: Schizophrenia
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
- News Quick Links
 | News Central | | Health Watch | |
| Latest Health News | | Health In Focus | |
| News Category (500+) | | Breaking Health News | |
| Popular News | | Celebrating Life | |
| Health News and Press Release | | Medindia - Exclusive | |
| News Photo Gallery | | India Special | |
| News Video Gallery | | Lifestyle and Wellness | |
| News From Other Resources | |||
 |
Schizophrenia
Complete Medindia Resources
|
| News Categories: |
| » | Schizophrenia Drug Differentiates Cancer Stem Cells into Less Threatening Cells |
| » | Docs Who Seldom Meet Drug Reps Continue to Prescribe Drugs With FDA “Black Box” Warnings |
| » | Revision in Quality Standards for Heparin |
| » | Acne Drug Users At High Risk of Developing Eye Infections |
| » | Patients Who Take Antidepressants When in ICU More Likely to Die |
| More Drug News | |
|
Drug Related News |
||||||||
| » | Schizophrenia Drug Differentiates Cancer Stem Cells into Less Threatening Cells | » | Docs Who Seldom Meet Drug Reps Continue to Prescribe Drugs With FDA “Black Box” Warnings | |||||
| » | Revision in Quality Standards for Heparin | » | Acne Drug Users At High Risk of Developing Eye Infections | |||||
| » | Patients Who Take Antidepressants When in ICU More Likely to Die | » | New Tablet Coating Product by Ideal Cures, In Geneva | |||||
| » | Prednisolone Benefits Patients With Bell's Palsy | » | 'Orphan' Sleep Drug may Fight Cancer | |||||
| Read More >> | ||||||||
